Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R L Basser

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Australian and New Zealand Journal of Medicine|June 5, 1998
Progress in management of acute myeloid leukaemia (AML) in Australia since 1980: a single institution retrospective studyD M Thomas, J F Seymour, J Szer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2002
Treatment with the novel anti-angiogenic agent PI-88 is associated with immune-mediated thrombocytopeniaM A Rosenthal, D Rischin, G McArthur, et al.
Growth Factors (Chur, Switzerland)|May 4, 2001
Pharmacokinetic analysis of pegylated megakaryocyte growth and development factor in humansR H De Boer, L K Roskos, E Cheung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 1995
Adjuvant treatment of high-risk breast cancer using multicycle high-dose chemotherapy and filgrastim-mobilized peripheral blood progenitor cellsR L Basser, L B To, C G Begley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2000
Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancerR L Basser, C Underhill, I Davis, et al.
Lancet (London, England)|November 9, 1996
Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancerR L Basser, J E Rasko, K Clarke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 1998
Phase I and pharmacokinetic study of KRN8602 alone and with filgrastim in patients with advanced cancerK Clarke, R L Basser, D Maher, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1997
Pharmacokinetics and pharmacodynamics of MX2 hydrochloride in patients with advanced malignant diseaseD J Morgan, J S Hill, K Clarke, et al.
Cancer Chemotherapy and Pharmacology|April 2, 1998
Effect of filgrastim on the pharmacokinetics of MX2 hydrochloride in patients with advanced malignant diseaseD J Morgan, J S Hill, K Clarke, et al.
Blood|May 1, 1997
Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancerR L Basser, J E Rasko, K Clarke, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Australian and New Zealand Journal of Medicine|June 5, 1998
Progress in management of acute myeloid leukaemia (AML) in Australia since 1980: a single institution retrospective studyD M Thomas, J F Seymour, J Szer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2002
Treatment with the novel anti-angiogenic agent PI-88 is associated with immune-mediated thrombocytopeniaM A Rosenthal, D Rischin, G McArthur, et al.
Growth Factors (Chur, Switzerland)|May 4, 2001
Pharmacokinetic analysis of pegylated megakaryocyte growth and development factor in humansR H De Boer, L K Roskos, E Cheung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 1995
Adjuvant treatment of high-risk breast cancer using multicycle high-dose chemotherapy and filgrastim-mobilized peripheral blood progenitor cellsR L Basser, L B To, C G Begley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2000
Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancerR L Basser, C Underhill, I Davis, et al.
Lancet (London, England)|November 9, 1996
Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancerR L Basser, J E Rasko, K Clarke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 1998
Phase I and pharmacokinetic study of KRN8602 alone and with filgrastim in patients with advanced cancerK Clarke, R L Basser, D Maher, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1997
Pharmacokinetics and pharmacodynamics of MX2 hydrochloride in patients with advanced malignant diseaseD J Morgan, J S Hill, K Clarke, et al.
Cancer Chemotherapy and Pharmacology|April 2, 1998
Effect of filgrastim on the pharmacokinetics of MX2 hydrochloride in patients with advanced malignant diseaseD J Morgan, J S Hill, K Clarke, et al.
Blood|May 1, 1997
Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancerR L Basser, J E Rasko, K Clarke, et al.
Pageof 4